Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

Volumn 2, Issue 1, 2004, Pages 201-207

  Wabbijn, Marike ^a   Balk, Aggie H M M ^a   van Domburg, Ron T ^a   Vantrimpont, Pascal J M J ^a   van Riemsdijk, Iza C ^a   Baan, Carla C ^a   Weimar, Willem ^a   van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INOLIMOMAB; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FOLLOW UP; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; NEOPLASM; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SURVIVAL;

ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-2; SURVIVAL ANALYSIS;

EID: 20444496960     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)